Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12)
dc.contributor.author | Mehta, L | |
dc.contributor.author | McNeill, M | |
dc.contributor.author | Hobart, J | |
dc.contributor.author | Wyrwich, K | |
dc.contributor.author | Poon, JL | |
dc.contributor.author | Auguste, P | |
dc.contributor.author | Zhong, J | |
dc.contributor.author | Elkins, J | |
dc.date.accessioned | 2016-10-03T13:50:52Z | |
dc.date.available | 2016-10-03T13:50:52Z | |
dc.date.issued | 2015-05 | |
dc.identifier.issn | 1352-4585 | |
dc.identifier.issn | 1477-0970 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/5550 | |
dc.description.abstract |
Background: The 12-question Multiple Sclerosis (MS) Walking Scale (MSWS-12v1) is a widely-used patient-reported outcome (PRO) measure of walking ability in MS. Objective: To estimate the magnitude of an important change in MSWS-12v1 scores for the interpretation of meaningful subject-level improvements across a 6-month trial of MS patients with walking disability. Methods: MOBILE was a 6-month exploratory study assessing fampridine’s effect on walking ability in 132 people with MS. Three PRO measures assessed walking ability: MSWS-12v1, EuroQol 5-Dimension-5 Level (EQ-5D-5L) mobility question, and a patient global impression of change (PGIC) in overall walking ability. Pre-specified anchor- and distribution-based analyses estimated the MSWS-12v1 change scores representing an important change for participants. Results were triangulated to propose a single best value indicating meaningful improvement. Results: Using Baseline to Week 2 through Week 24 change scores, anchor-based analyses demonstrated mean and median improvements of 5.2-6.6 (PGIC) and 9.7-13.4 (EQ-5D-5L mobility) points on the MSWS-12v1 indicated meaningful improvements. The distribution-based estimate was 6.8 points. Triangulation across the results suggested an 8-point reduction in MSWS-12v1 score represents an important subject-level change in these participants. Conclusion: In similar MS clinical trials, an 8-point improvement on the MSWS-12v1is a reasonable estimate of meaningful improvement in walking ability. | |
dc.format.extent | 813-814 | |
dc.language.iso | en | |
dc.title | Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12) | |
dc.type | journal-article | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354258600064&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 6 | |
plymouth.volume | 21 | |
plymouth.publication-status | Published | |
plymouth.journal | MULTIPLE SCLEROSIS JOURNAL | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.identifier.eissn | 1477-0970 | |
dc.rights.embargoperiod | 12 months | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
rioxxterms.type | Journal Article/Review |